Enanta Pharmaceuticals (ENTA) Other Accumulated Expenses (2012 - 2026)

Enanta Pharmaceuticals has reported Other Accumulated Expenses for 15 years, with the latest figure at $310000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 80.27% year-over-year to $310000.0; the trailing twelve-month figure through Mar 2026 stood at $310000.0 (down 80.27% YoY), and the FY2025 full-year result was $405000.0, down 86.88% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $310000.0, down from $2.1 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $6.9 million in Q4 2022, with the low at $310000.0 in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $2.6 million across 5 years, with a median of $1.6 million in 2025.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 541.91% — and 2025, when it sank 86.88%.
• Enanta Pharmaceuticals' Other Accumulated Expenses stood at $6.9 million in 2022, then slumped by 63.76% to $2.5 million in 2023, then slumped by 41.7% to $1.4 million in 2024, then soared by 41.66% to $2.1 million in 2025, then sank by 84.91% to $310000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $310000.0 (Q1 2026), $2.1 million (Q4 2025), and $405000.0 (Q3 2025), per Business Quant data.